Agomab receives FDA Orphan Drug Designation for AGMB-447 in idiopathic pulmonary fibrosis
AGMB-447 is an inhaled lung-restricted ALK5-inhibitor currently in a Phase 1 clinical trial Agomab Therapeutics announced that…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.